Rationale and prognosis of repurposed drugs with risk stratification of patients in oxygen support in COVID-19: A systematic review and meta-analysis

Esther Jebarani Elangovan^{*1}; Vanitha Shyamili Kumar^{*2}; Adhithyan Kathiravan²; Raghav Mallampalli²; Tiju Thomas²; Gnanasambandam Subramaniyam³

*= these authors contributed equally and share first authorship

¹Department of Biotechnology, Anna University, Chennai, India

²Indian Institute of Technology – Madras, Chennai, India

³Department of Pediatric Cardiology, Madras Medical College, Chennai, India

Corresponding Author

Dr.Tiju Thomas Associate Professor, Indian Institute Of Technology, Madras, Chennai, India – 600036 Email: tijuthomas@iitm.ac.in, tt332@cornell.edu Keywords: COVID-19, tocilizumab, invasive mechanical, hypertension, comorbidities, diabetes Word count : 5393 Tables : 1 Figures : 6 Supplementary material: 1

Abstract

There has been rapid development of clinical trials conducted on antivirals, immunomodulators, and other therapies against COVID-19. The rising number of trials has led to duplication and a need for curation of available outcomes from treatments that have been followed across the world. We have conducted a systematic review and meta analysis that focus on evaluating the clinical outcomes of repurposed drugs against COVID-19 including Tocilizumab, Remdesivir, Dexamethasome, Lopinavir-ritonavir, Favipiravir, Hydroxychloroquine and Convalescent plasma therapy. Twenty-nine articles were included in this study after thorough literature search and performed subgroup analyses based on disease severity levels. Random effects model was

adopted to estimate overall treatment effect and heterogeneity. Subgroup analysis on mortality rate showed significant overall effect in the treatment group of studies having critically ill patients (p<0.01). Meta-regression analysis was performed to study the association of drug efficacy in patients with different comorbidities and factors that influence the patient's prevalence in non-invasive and invasive ventilation support. Overall, our study confirmed that tocilizumab may probably reduce the mortality (<10%) of patients with COVID-19 with faster recovery time and reduce the risk of patients with lung disease in falling into oxygen support (P=0.02). Patients on Remdesivir showed no significant associations of comorbidities with risk of falling into oxygen supports. Hydroxychloroquine was found to be inefficacious in COVID-19 patients (OR 0.64; 95%CI [0.47-0.86]). Dexamethasone had marginal effect on overall mortality rate (OR 1.19; 95%CI [1.05-1.35]). There was also evidence suggesting that combination therapies (Serpin + Favipiravir) were helpful in reducing the mortality rate in COVID-19 patients under invasive support.

Introduction

The first incidence of novel coronavirus (COVID-19) was identified in patients with severe respiratory disease in Wuhan, China. Since then, COVID-19 outbreak has grown to 32.7 million cases resulting in 991,224 deaths as on 27th September, 2020 across the world. The effect of and response to the virus is varied based on the immune systems [1] environment risks [2], pre-existing health conditions [3, 4], sex differences [5] and so on across different populations in and different countries. The virus has debilitated the global community and will continue to do so until an effective vaccine or antiviral is developed.

The ability of the virus to spread rapidly, causing increased risk of deaths in patients with existing health conditions has been considered to be the most alarming feature of COVID-[6,7] At present, there are no targeted therapies or vaccines available for COVID-19. Based on previous outbreaks like Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) in 2003 [8–10] and the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in 2012 [11–13], medical community has been working swiftly by repurposing the drugs and evaluating their efficacy in the treatment of the novel coronavirus. Current treatments are primarily based on factors such as combination of drugs, severity level of disease and respiratory support. Treatment paradigms follow WHO guidelines or those offered by health authorities in each country. Drugs such as Hydroxycholoroquine (HCQ) which were initially reported to be effective in treatment were later found to have limited positive effect on the infected [14]. Later analyses have shown other immune therapies, repurposed antivirals found to have positive effect on patients in particular phases of treatment [15,16].

Lack of specific treatment and drug therapies for COVID-19, has led the scientific and medical communities to run several drug trials in the past seven months. These studies generated a huge collection of data regarding the drug efficacy, adverse effects and its specificity towards certain populations. The aim of this study is to design and implement a data driven meta-analysis of existing literature and available outcomes regarding treatment for novel coronavirus. We have explored the effect of emerging treatments widely followed by present medical guidelines across countries including drugs like Tocilizumab (TCZ), Remdesivir (RM), Favipiravir (FPV), Dexamethasone (DM), LPV-r (LPV-r) and Convalescent Plasma (CP) therapy on patients at different severity levels of COVID-19. In addition to that, we have attempted to manifest the correlation of drug's ability to treat patients on invasive and non-invasive oxygen support with comorbid conditions like hypertension, diabetes, and cardiovascular diseases. We believe that our findings may help the medical and scientific community to better understand the association of temporal relationships of drug usage during different stages of disease on patients with pre-existing health conditions.

Methods

We report a systematic review and meta-analysis, as per the recommendations of PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statements [17]. Our work has not been registered under PROSPERO.

Search Strategy and Study Selection

We systematically searched databases including PubMed, medRxiv and Scopus for research articles published from anytime up to 1st August, 2020. An advanced search was performed with the following keywords: (Remdesivir OR Favipiravir OR Lopinavir/Ritonavir OR Tocilizumab

OR Dexamethasone OR Convalescent Plasma OR Hydroxychloroquine OR Arbidol OR Corticosteroids) AND ("COVID-19" OR "SARS-CoV-2" OR "2019 nCoV") AND (Moderate OR Severe OR Critically ill OR Hospitalized OR Oxygen Therapy OR Invasive Mechanical Ventilation). The drug names in the keywords were selected from the World Health Organization (https://www.who.int/), Indian Council of Medical Research (https://www.icmr.gov.in/), and Ministry of Health and Family Welfare (https://www.mohfw.gov.in/) COVID-19 protocol guidelines. Additionally, we screened the references of the included articles to obtain more relevant papers for the study.

The following articles were excluded from the analysis: duplicates, review papers, editorials, letters, comments, other language manuscripts and studies tested on in-vitro cell culture and invivo animals. Inclusion criteria for the study were: i) randomized (RCT) or non-randomized clinical trials (nRCT), prospective or retrospective observational studies (cohort study and case series) ii) research articles, preprints and preliminary reports with comparators (Treatment *Vs*. Control) or combination of treatment modalities or studies without control group iii) study population could be any age, sex and any region in the world, diagnosed with COVID-19 with either laboratory test-confirmed or Chest computer tomography (CT) iv) any one of these outcomes reported: mortality rate, recovery rate, viral clearance period, clinical improvement of patients in oxygen therapy or invasive mechanical ventilation (IMV) after drug treatment.

Data extraction

Data extracted from the included study articles were updated on a google spreadsheet. Any ambiguity in data extraction was clarified by discussion and consensus of the authors. Clinical insights were consistently sought. The following features were extracted: author, study type, date

of publication, study period, study place, drug name, cohort size, gender, age, severity condition (mild, moderate, severe and critical); treatment combination, time from symptom onset to the treatment, dosage details, exclusion criteria of drug; precondition of patients (PaO2:FiO2, SpO2 levels, respiratory rate), comorbidity, patients requiring respiratory support such as low flow oxygen support, high flow or Non-Invasive mechanical Ventilation (NIV), IMV or extracorporeal membrane oxygenation (ECMO) (during admission and follow-up); clinical improvement length, viral clearance period; mortality rate; recovery rate and adverse effects. All the data were individually extracted for subgroups (treatment group, control or comparator) and overall outcomes of all the treatments were summarized together and plotted using ggplot2 [18] in R.

Risk of bias assessment

We used RoB 2.0 [19] and ROBINS-I [20] tools of Cochrane risk of bias assessment for evaluating RCTs and observational or nRCTs. Robvis package [21] from R was used for the visualization of risk bias assessment. The Newcastle-Ottawa scale (NOS) was used to assess single-arm studies [22]. The use of this scale is more sensible to control the quality level of the cohort study [23].

Statistical analysis

To evaluate the drug treatment effects between control and test groups, an odds ratio was obtained to measure probability of events occurring between groups at disease severity. The intervention effect distribution was estimated using the Random Effects Model (REM), which is provided as an estimate of 95% confidence interval. I^2 statistic was used to measure heterogeneity within and between studies. This was performed using metafor package V2.4.0

[24] in R V4.0.2. Overall proportion of all single armed studies were calculated using metaprop [25] program in R. Meta-regression was performed to assess the correlation of drug efficacy in patients at different oxygen therapy stages with comorbid conditions using lm function in R. A pvalue of ≤ 0.05 is considered as statistically significant in all our studies unless stated.

Results

Overall, 15,831 records were identified by our searches. On removing redundant entries, 3095 numbers of papers were retained. After exclusion of review articles, 29 clinical studies (24 published and 5 pre-prints) met our eligibility criteria (PRISMA flow chart Figure 1). All these were available online between 11th March, 2020 to 22nd July, 2020. After definitive selection of articles, there were eight therapeutic agents in total found from 29 studies having 14,114 COVID-19 patients involved were compared in our meta-analysis. These eight agents included TCZ (trialed on 684 participants), CP (95), RM (158), DM (2104), HCQ (912), LPV-r (215), Arbidol (137), FPV (2383) and Standard care or placebo (6344). Nine (6 published and 3 pre-prints) of 29 included studies were single-arm trials without a comparator. The description of the participants, treatment, clinical outcomes and the key findings of all the included studies are presented in Table 1.

Subgroup analyses based on disease severity levels

By pooling articles based on disease severity levels, studies were subgrouped as 1) mild/moderate 2) severe (Figure 3). Odds ratio of mortality rate for studies including mild/moderate patients found to have higher 95% Confidence Interval (CI), P Value of 1.00with $I^2 = 0\%$ indicating no observed heterogeneity. However, articles with patients at high risk/severe disease symptoms showed P Value < 0.001 and heterogeneity measure (I^2) of 87.5%. Most of the

studies classified under severe subgroups had small 95% CI and showed positive effects of drugs in the treatment group. On the other hand, a greater part of studies under mild/moderate subgroup indicated the null effect of the drug on the treatment group with long 95% CI. Of all the drugs included in the severe subgroup, TCZ was found to perform well on patients at high risk (OR 27.50 [5.39-140.24]; 2.70 [0.82-8.94]) [26], followed by CP therapy (OR 2.12 [0.70-6.38]; 1.70 [0.63-4.59]).

Of two articles published on RM, one showed less response on treatment group [27] (OR 1.81 [1.15-2.83]) while other had null effect (OR 0.91 [0.41-2.03]) [28]. The failure of the latter trial on Remedesivir is due to the small sample size with 2:1 randomisation. Both the studies showed an insignificant mortality rate between control and test groups [27,28]. DM had a marginal positive effect on patients at high risk (OR 1.19 [1.05-1.35]). HCQ showed negative effects on treatment groups under severe conditions (OR 0.64 [0.47-0.86]) [29]. This study had a large cohort (n=1376) of hospitalized COVID-19 patients suggesting that HCQ use had no potency for end stage intubation or death. Overall, REM for all studies from all subgroups showed a significant P Value of 0.001 and heterogeneity measure (I^2) of 72.2%.

Figure 4 shows a visual summary of a patient's mortality from different drug trial studies with no placebo/control. The results of included single armed studies, with 95% C.I and the pooled proportions are provided. Overall effect of drugs on COVID-19 patients showed a significant mortality proportion of 0.12 (P < 0.01) with heterogeneity measure (I^2) of 72%. Most of the included studies had lower mortality proportion (< 0.1) except two studies on TCZ [30,31] having > 0.2 proportion.

Factors associated with the prevalence of patients in different oxygen therapies.

We performed meta-regression analysis to understand the association of factors influencing a patient's dependency on life supporting ventilation treatments. A set of variables that may likely influence the COVID-19 patients landing into non-invasive and invasive oxygen supports were identified. The variables included were time from symptom onset to treatment, treatment duration, mortality rate and comorbidities of patients (hypertension, diabetes, heart disease and lung diseases). Of all the drugs included, TCZ and RM had enough number of studies (14) with potentially relevant oxygen support information (supplemental oxygen/ NIV/ IMV) to carry out the analysis. Results showing the multivariate meta-regression for all TCZ studies are shown in Figure 5. A total of 376 patients were under respiratory support before the treatment, and 195 remained at the end of treatment. In this multivariate meta-regression model, comorbidities factors showed association with prevalence of patients in non-invasive support (Figure 5a and 5b). There was a significant positive correlation between prevalence of patients on TCZ in non invasive support and hypertension condition (P = 0.02) (Figure 5b). On the other hand, a significant negative correlation with patients having lung disease and their existence in noninvasive support was identified (P = 0.03) (Figure 5b). Additionally, patients with pre-existing diabetes conditions significantly observed to have no association with their prevalence in noninvasive support (P = 0.02) (Figure 5b).

There was no significant association identified on comparing the patients prevalence in invasive ventilation supports (ECMO) and its affecting factors. Similar to the non-invasive case, positive correlation was observed between the number of patients with hypertension and increased risk of falling into invasive oxygen support. On the other hand, patients with diabetes when treated on TCZ showed negative correlation with their prevalence in invasive ventilation support.

Furthermore, patients treated with TCZ under invasive support had no association with early treatment onset, and comorbidities conditions including pulmonary, renal and heart diseases. Meta-regression on RM revealed no association of the patient population in oxygen therapy with any of the dependent variables except time from symptoms onset. It showed a negative correlation with the patient population under the invasive group.

The overall clinical outcomes in control and test for each treatment were compared and represented as a bar plot (Figure 6). The percentage of death in the TCZ group was found to be lowest (<10%) among all treatments compared in this study. Additionally, patients in the TCZ group found to have faster recovery (clinical improvement duration 7days) than the control group and other treatments. However, there was no much difference in patients' percentage in the invasive support from the time of admission to follow-up. HCQ was the only test group where the death rate relatively scaled up than in the control group. The clinical outcomes of control and test groups from DM studies showed no significant difference (it was specific for significant reduction of death in IMV support). Although a shorter duration of clinical improvement was observed among TCZ, DM and RM treatments. A good rise in negative conversion rate of the viral RNA (during follow-up) was seen in CP and FPV therapy compared to the control groups. The studies including RM and LPV-r observed to show lower incidence of severe adverse events, the percentage are very much comparable with that of their control group.

Risk of bias assessment

The risk of bias score evaluated for 29 included studies comprising 12 RCTs, 1 nRCT, and 16 observational (12 retrospective, 3 prospective and 1 case series) are presented in Figure 2 and

Table S2. The overall judgments for 15 studies were high risk or poor quality, 10 at moderate or fair quality and 4 at low risk of bias.

Discussion

Although mortality rate is 1% of the total population of the world [32] COVID-19 has caused 991,224 deaths till now, and no therapeutic agent has received Food and Drug Administration (FDA) approval yet. There are many clinical studies reported on repurposed drugs for COVID-19 treatment. This meta-analysis indicates 29 of such studies involving 14,114 patients with COVID-19 and assess drug efficacy on the key outcomes, including mortality rate, viral clearance, clinical improvement, oxygen support, invasive ventilation, comorbid factors (diabetes, hypertension, heart disease, lung disease and renal disease) and adverse events.

According to the pooled results in subgroup analyses, assessing the severity of the disease, TCZ is found to be more effective in reducing the mortality rate (OR 27.50 [5.39-140.24]) of severe COVID-19 patients (Figure 1). TCZ, an approved antagonist of IL-6 receptor in rheumatoid arthritis with moderate to severe condition [33]. This is also considered as a selective cytokine inhibitor in COVID-19 [34], where multiple clinical studies have evaluated the safety and efficacy of TCZ in the severe stage of the disease.

In Capraa et al.'s study, a greater significance was seen in survival rate (p=0.004) and 92% recovery in TCZ treated patients as compared to the control [26]. But, Campochiaro's study reveals no statistical difference in mortality rate (TCZ 15% *Vs.* control 33%) and clinical improvement (69% *Vs.* 61%), due to small cohort size [35]. But still, there is a slight significance seen in mortality rate in our finding with odds of 2.70, showing TCZ is little superior over standard therapy. In fact, Nicola et al. concluded that early use and low dosage of TCZ has

shown to be effective and reduces mortality rate (94%) without any adverse events, but they are limited with small study groups and no evidence exists for the same, with treatment at later stages of respiratory failure [36]. Another prospective study supports Nicola's results suggesting that a timely administration of TCZ before lung injury improves outcomes of severe COVID-19 [30]. In spite of that, three retrospective studies on TCZ [31,37,38], where 2 studied with cohort-control and 1 with single- arm, managed to show consistent results in relation to risk of IMV or death or ICU admission.

The first study has a larger cohort of 544 serious COVID-19 patients, showing a decrease in IMV risk up to 27% in the TCZ group than standard 41.5%. But, this study limits with a residual confounding that there were 4 patients with renal insufficiency or cancer in the TCZ group whereas it was 15 in the standard [37]. Similarly, the second study even with a smaller cohort could observe that TCZ treatment strongly reduces ICU admission or death (25% *Vs.* 72%, p = 0.002) or IMV support (0% *Vs.* 32%, P = 0.006) than standard care in the critically ill COVID-19 patients [38]. The third single-arm study with 100 patients also shows clinical improvement in 77% patients having respiratory support or 74% of 43 ICU patients by day-10 [31]. Additionally, two studies shows good improvement in the SpO2 levels (89% to 97%, day 1-10) [39] and PaO2:FiO2 ratio (152±53 to 302.2 ±126, day 0-14) of TCZ treatment [40].

A previous systematic review on TCZ reported 28 studies conducted in many different places; the results of most of these studies were favorable to TCZ therapy in severe and critically ill COVID-19 patients than standard therapy [41]. Based on this, TCZ is safe in treating both early and late stage respiratory conditions of COVID-19, but so far, no RCT has been reported in treating the severe groups, where the RCT is still on-going to measure the efficacy and safety of this treatment in case of severe COVID-19 [42].

CP is another type of immune therapy that shows less or no significance (OR 2.12 [0.70-6.38]; 1.70 [0.63-4.59]) between the control and the treatment in the subgrouping of 2 RCTs included. Results from a RCT using CP have shown that mortality rate (p=0.95) and improvement of day-15 disease severity (p=0.58) were not significant when compared to the standard group. The study also shows that COVID-19 patients already have enough neutralizing antibody titers than donors and suggests that the use of CP at early symptom onset [43]. Another RCT also showed similar results that the mortality and clinical improvement were found to be insignificant. Despite this, they showed a higher significance (87.2% CP *Vs.* 37.5% STD) in viral load negativity within 72 hrs after CP transfusion in severe COVID-19 patients [44]. Limitation in both studies was that they were soon terminated before attaining enough sample size which prevented definite conclusions of clinical benefits.

In our post-search, a large RCT done on CP management was found. This enrolled almost 464 moderately ill COVID-19 patients, and showed results in line with 2 previous RCTs, that mortality was not significantly different between CP treated and control groups 14.5% *Vs.* 13.5% [45]. According to these reports, CP therapy has shown to be more efficient in early negative conversion of viral RNA, but no effect in reducing the mortality rate of moderate-severe COVID-19 patients.

RM shows less or no significance in our subgroup analyses (OR 1.81 [1.15-2.83]; 0.91 [0.41-2.03]. This shows that it is not effective in reducing the mortality rate for severe COVID-19 patients. Two RCTs with placebo-controlled have been reported, one [27] of which has a larger study size with improvised protocol than the other [28]. The first study favors RM over placebo with short recovery time (11 *Vs.* 15 days) for all clinical outcomes except patients on IMV or ECMO. They further suggest that it is supportive for hospitalized and low supplemental oxygen

support patients [27]. A Second study trialed 2:1 randomization with limited sample shows no significance in reductions of viral load or duration of clinical improvement in severe COVID-19 patients [28]. Both RCTs describe that the mortality rates were insignificant between treatment and placebo. Also recommend that RM could be given as an antiviral agent in combination with other therapy before the condition progresses to need for IMV [27,28].

Subsequently, Gein et al. study on compassionate-use of RM, shows 22% death and 70% clinical improvement among patients. Also, 50% (25/53) of severe patients with age group 70 or older were discharged. However, adverse events occurred in 60% of patients (such as elevated hepatic enzymes, rash, hypotension and renal impairment) and serious adverse events in 23% (multiple-organ-dysfunction syndrome, acute kidney injury, septic shock and hypotension). This was caused by RM treatment alone [46,47].

Two other studies [48, 49] randomized moderate and severe patients with RM for either 5-day or 10-day courses. The clinical improvement of severe patients (without receiving mechanical ventilation) was not significant (64% *Vs.* 54%) between the two courses [48]. Anyhow, in moderate patients, the 5-day course had statistically significant clinical status when compared to standard care (OR 1.65 95% CI, 1.09-2.48; p = .02), whereas the 10-day course showed no effect [49]. Majority of these study outcomes suggest that RM can be used for hospitalized and lower respiratory tract infectious COVID-19 patients.

Regarding DM, Horby et al. have published a well-designed largest RCT that enrolled the highest population size (n=6425), when compared to any other studies included in this metaanalysis. The study shows a low dose of DM is most effective in patients on IMV or ECMO than without respiratory support, where the risk of death is reduced significantly in DM group than

usual care (29.3% *Vs.* 41.4%) of critically ill COVID-19 patients. Anyhow, the overall mortality rate of all groups including those without respiratory support does not seem to have much difference (22.9% *Vs.* 25.7%) [50], which is why the subgroup analysis in our study shows a marginal effect in mortality rate (OR 1.19 [1.05-1.35]). Therefore, DM could be recommended in treating long term symptom COVID-19 patients, requiring IMV than recent symptom onset.

The studies on HCQ and antivirals (LPV-r, arbidol, FPV) in mild-moderate subgroups show a null effect (OR 1.10 [0.29-4.11]) (Figure 1), since no event of death occurred in both control and treatment groups. However, many other clinical outcomes related to these drugs are reported. HCQ, an anti-malarial agent presumed to exert antiviral and immunomodulating effects in COVID-19. But, Geleris et al. studied a large cohort (n=1376) of hospitalized COVID-19 patients and suggested that HCQ use had no potency for end stage intubation or death (hazard ratio, 1.04; 95% CI, 0.82 to 1.32). This study had a poor score (OR 0.64 [0.47-0.86]) in the severe subgroup coupled to the mortality (Figure 1). Two RCTs from China studied HCQ with a small number of mild-moderate patients. The first is a preprint and only partially confirmed the drug effect on symptomatic outcome (like fever and cough) [51]. The other study shows no significance in viral clearance between HCQ plus standard Vs. standard alone treatment, in addition more adverse events were found high in HCQ group [52]. Recent research shows HCQ inhibits trained immunity by an epigenetic modulation. This prevents the antiviral effects of the bodily innate immune response against the SARS-CoV-2 infection [53]. Together, these results indicate that HCQ is not a promising rescue option for mild-moderate and severe COVID-19 patients.

LPV-r or Arbidol alone shows little benefit for clinical outcome of mild-moderate COVID-19 patients [54], but Deng's study showed that combined effect is more favorable [55]. A

retrospective study commends, LPV-r has a more rapid effect in viral clearance than HCQ [56]. Although Cao et al. performed a RCT on LPV-r found no benefit in mortality reduction or receiving oxygen support in case of severe COVID-19 patients. Thus no effect was seen in the mortality rate (OR 1.40 [0.71-2.76]) of the severe subgroup (Figure 1). Their finding says the positive viral RNA appeared till the end of trial in LPV-r group (40.7%), but it was not confirmed with the presence of viral infection. The study limits without blinding which might have influenced the outcome and premature discontinuation (14%) of the treatment [57]. Therefore, the LPV-r treatment seems to have antiviral benefits during mild COVID-19 condition.

FPV, an inhibitor of RNA-dependent RNA polymerase of viral RNA, evaluated by in-vitro studies to be active against COVID-19. An observational study conducted in Japan, provided FPV (high dose of 1600 mg twice day 1 followed by 600 mg twice a day for 5 days) to a large population (n=2158) on compassionate basis and observed mortality rate of 1918 COVID-19 patients after a month was higher in severe group (31.7%)

An observational study with 2158 COVID-19 patients, studied FPV use on compassionate basis. They show mortality was higher in the severe group (31.7%) when compared to mild (5.1%) and moderate (12.7%) by day-30. Likewise, the rate of recovery was lower in the severe group (14.7%) than the other two conditions (61.7% and 42.7%). Also, deaths were frequent in elderly and 24.65% of patients posed adverse events with FPV therapy. The study unfortunately is limited since it contains no background data of patients though they are registered from 407 hospitals [58]. A study in Thailand favors the use of FPV with 100% of clinical improvement in 27 hospitalized patients (without oxygen support) and 83.3% in 30 serious conditions (requiring supplemental oxygen or IMV) at day 28. However, the study is limited by the use of additional

agents such as chloroquine and hence could not find the actual impact of FPV [59]. Another study shows, by day-7, FPV had no difference in recovery rate when compared with Arbidol therapy for moderate COVID-19 patients [60].

Synthetic serine protease inhibitors (serpins) were earlier used to treat diseases like Acute myocardial infarction, Ischemic stroke and Pulmonary embolism [61]. More recently Nafamostat, a Serpin was found to prevent the proteolytic activity of transmembrane protease serine 2 (TMPRSS2) and thus inhibits the viral fusion with the host cells [62,63]. The combination of two therapies (serpin and FPV), may allow the inhibition of viral entry as well as the replication. A small case series shows that FPV in combination with Nafamostat was found to have benefits on severe COVID-19. In which, 8 of 11 patients were extubated and 9 discharged from ICU. But still there is no convincing evidence supporting this study [64]. Taken together, FPV use is efficacious in mild-moderate COVID-19 patients. But for severe or critically ill conditions, the addition of Serpins with the FPV may be helpful.

In summary i) TCZ is effective in severe COVID-19, but requires a RCT to validate the results. ii) DM works only on patients with IMV in reducing mortality, however several unresolved questions still exist. iii) RM benefits patients without having IMV support. iv) CP and LPV-r can cure only mild illness and CP was found to be efficacious in bringing down the viral load in at least hours. v) HCQ has no potency or antiviral effects. vi) FPV when used in combination with serpins found to have additive effects on severe COVID-19, but more findings are required to assess the drug tolerability.

One previous meta-analysis was reported already on repurposed drugs by June 9 (pre-print), however the current study has added more therapeutic agents with its recent trials including a

huge number of patients. Our study is bound by limitations of much high risk quality evidence. In addition, few non-comparable single-arm observational studies and smaller cohorts are underpowered to assess the clinical outcomes that were addressed.

Conclusion

Based on the available evidence, this analysis has found immunotherapy (TCZ) was superior to antivirals in most of the clinical outcomes. Additionally, a low dose of DM is much helpful in patients on IMV or ECMO with significant reduction of death risk than standard care. Although it has a marginal effect on live-saving without respiratory concerns. HCQ was found to have no clinical effects for COVID-19, whereas it plays a role in inhibiting the trained immune system. LPV-r, not efficacious in severe COVID-19, yet has some antiviral effects in mild conditions. The use of CP rapidly reduces viral load within a few hours in all stages of COVID-19. The results of HCQ and LPV-r were in line with the recently reported 6-arm RECOVERY clinical trial (NCT04381936). But the trial with TCZ and other monoclonal antibody cocktails in the 6arm are still on-going, the results of which may provide an optimal dosage and safety details for an appropriate benefit of the therapy. From meta-regression analysis, a significant correlation of patients exposed to TCZ with hypertension and higher risk of falling in non-invasive oxygen support (P=0.02) was observed. On the other hand, patients on TCZ having lung diseases had lower prevalence in non-invasive support. Antivirals RM and FPV were recommended as a combinatorial therapy with other agents. A 10-day course of RM has speedy recovery in hospitalized patients (without IMV) and a 5-day course is safe in moderate COVID-19. FPV alone treats patients before the end stage of COVID-19 patients. But the combinatorial use of Serpins with FPV may be efficacious for even critical patients. Furthermore, high quality evidence is required to evaluate its usage in severe or critical COVID-19.

Table 1. Characteristics of Baseline characteristics and key outcomes of included studies

Author	Study type(Country)	Participants	Treatment	Comparison	Outcomes	Key findings	Overall risk of bias
			Tocilizu	mab			
Campochiaro et al. [35]	Single-centre retrospective observational study (Italy)	Severe COVID-19 (n=65)	Tocilizumab i.v. at 400 mg once plus standard care. Second dose 400 mg after 24 h in case of respiratory worsening (n=32)	Standard care without tocilizumab (n=32)	Survival; 2 point decrease six- category ordinal scale; clinical improvemen t at day-28; adverse events	At day 28 TCZ Vs. STD: No significance in mortality (15% Vs. 33%) (p = 0.15), where age \geq 75 as predictors of death and clinical improvement (69% Vs. 61%)(p = 0.61), where PaO2:FiO2 \geq 100 as predictors; Bacteremia (13% Vs. 12%)	High risk (ROBINS -I)
Kewan et al. [65]	Single-centre retrospective observational study (USA)	Severe COVID-19 (n=51)	Tocilizumab i.v. 8 mg/kg and received a maximum of 400 mg for 60 min once plus standard care (n=28)	Standard care without Tocilizumab (n=23)	Clinical improvemen t; 2 point decrease six- point scale or live discharge; adverse events	TCZ Vs. STD: Shorter duration of IMV (7 Vs. 10 days) and vasopressor (2 vs 5 days) in TCZ group; age ≥ 65 years on IMV had higher clinical improvement rate (40% Vs. 13%, p = 0.20); No significance in clinical improvement 76.5% Vs. 79.4%	High risk (ROBINS -I)

						by day 21	
Guaraldi et al. [37]	Single-center retrospective observational cohort study (Italy)	Severe COVID-19 (n=544)	Tocilizumab i.v. 8 mg/kg twice 12h apart (n=179)	Standard care without tocilizumab (n=365)	Risk of death or invasive mechanical ventilation, adverse events or severe adverse events	TCZ Vs. STD: Significant reduction in risk of IMV or death in TCZ group (adjusted hazard ratio 0.61 , 95% CI 0.40-0.92; p= 0.020); mortality reduced in TCZ treatment 13 (7%) Vs. 73 (20%) (p< 0.0001); new infections (13% Vs. 4%, (p< 0.0001))	Moderate risk (ROBINS -I)
Klopfenstein et al. [38]	Single-center retrospective case-control study (France)	Critically ill COVID-19 (n=45)	Tocilizumab 1 or 2 doses plus standard treatment (n=20)	Standard treatment without tocilizumab (n=25)	ICU admissions; death; IMV; discharge	Reduction in ICU admission/death (25% Vs. 72%, p = 0.002) or requiring IMV $(0\% Vs.$ 32%, P = 0.006) in TCZ group than control	Moderate risk (ROBINS -I)
Rossi et al. [36]	Multi-centre retrospective observational study (Italy)	COVID-19 patients with early stage respiratory failure (n=158)	Tocilizumab i.v. 400 mg or s.c.324 mg plus standard therapy (n=90)	Standard therapy without tocilizumab (n=68)	Clinical and laboratory results at day 5; IMV; death	Reduction of death (94%) in TCZ group at low dose in early stage respiratory failure; no difference in two administration modes ($p =$ 0.292); no adverse	Moderate risk (ROBINS -I)

						events	
Capraa et al. [26]	Single-center retrospective observational study (Italy)	COVID-19 patients requiring respiratory support except IMV (n=85)	Tocilizumab i.v. 400 mg once or s.c.324 mg once plus standard care (n=62)	Standard care without Tocilizumab (n=23)	Survival; respiratory followup; infections	TCZ Vs. STD: greater survival rate (HR 0.035; 95% CI, 0.004 to 0.347; p = 0.004), recovery (92% and 42.1%) and still hospitalized recovery (64.8% <i>Vs.</i> 0%) in TCZ group; no infections	Moderate risk (ROBINS -I)
Tomasiewicz et al. [39]	Multi-centre retrospective observational study (Poland)	Severe COVID-19 (n=28)	Tocilizumab i.v. 800 mg once (n=28)	No comparison	Clinical status at 24 hrs, 1 and 2 weeks; laboratory data; adverse events	TCZ increases SpO2 levels from 89% (Day 1) to 97% (day 10) (p \leq 0.001); 2 weaned mechanical ventilation within 24 hrs after first dose; 84% chest CT improvement in 2 weeks; death or slow improvement in patients associated with 2 or more comorbidities	Poor quality (NOS
Sciascia et al. [40]	Multi-centre prospective pilot study (Italy)	Severe COVID-19 adults (n=63)	Tocilizumab i.v. 8 mg/kg or s.c. 324 mg. Second administration s.c.	No comparison	Laboratory data; IMV; Safety	TCZ administration significantly increased survival	Poor quality (NOS

			1				
			162 mg before 24			within 6 days (HR	
			h (n=63)			2.2 95%CI 1.3-	
						6.7, p<0.05) and	
						Pa02:Fi02 ratio	
						from 152±53 (day	
						0) to 302.2 ± 126	
						(day 14) (p<0.05);	
						improvement in	
						D-dimer, ferritin,	
						C-reactive protein	
						levels and	
						lymphocytes count	
						(p<0.05)	
						TCZ	
						administration	
						showed 58% rapid	
						improvement at	
						24-72nr in	
						respiratory	
					Laboratory	then no TCZ. Du	
	Single conton				data at day	dav10, 77%	
	Single-center	Severe	Tocilizumab i.v.		10; ICU	day10.77%	Poor
Toniati et al. [31]	prospective	COVID-19	8mg/kg twice 12	No comparison	improvemen	respiratory	quality
	(Italy)	(n=100)	hr apart (n=100)		t; severe	acondition 54%	(NOS
	(Italy)				adverse	condition, 54%	
					events	invasivo	
						untilation 740/	
						of 12 ICL notionta	
						improved: 20%	
						mortality: 3%	
						Savara advarse	
						offoots	
						effects	

Montalva et al. [30]	Single-center prospective cohort study (Spain)	Hospitalized adults with severe COVID-19	Tocilizumab 600 mg (>75Kg) or 400 mg (<75Kg) once	No comparison	Death at Day7; admission to Intensive Care Unit (ICU), acute Respiratory Distress Syndrome (ARDS) and respiratory insufficiency ; adverse events	TCZ: Mortality(26.8%) was more frequent in test group with ARDS (HR 3.3; 95% CI, 1.3 to 8.5), respiratory failure was present (HR 3.13; 95% CI, 1.3 to 7.8); no serious adverse events	Poor quality (NOS
			Convalescen	l plasma		Cianificant	
Li et al. [44]	Multi-centre randomized open label study (China)	Severe or life- threatening COVID-19 (n=103)	Convalescent plasma transfusion 10 mL first 15 min, then upto 100 mL/ hr based on the patient's risk or tolerance, plus standard treatment (n=52)	Standard treatment without plasma (n=51)	Discharge; 2 points less 6-point disease severity scale; viral PCR test at 24,48 and 72 hrs and post- hoc day 7, 14 and 28	Significant increase in viral PCR negative conversion rate at 72 hrs in CP group than STD (odds ratio (OR) 11.39 (95% CI, 3.91- 33.18) P < .001); no significace in 28-day mortality (p= .30) or discharge (p= .12); adverse events in patients after transfusion were cured	High risk (RoB 2.0)
Gharbharan et al. [43]	Multi-centre randomized open label study	COVID-19 positive (RT- PCR test) (n=86)	Convalescent plasma i.v. 300ml plus standard care (n=43)	Standard care without plasma (n=43)	Overall mortality upto 60 days; 8-point	Recepients had high antibody titers than donors before transfusion;	High risk (RoB 2.0)

	(Netherlands)				disease- severity scale at day 15; safety outcomes	no serious adverse events; clinical improvement (p=0.58) or mortality (p=0.95) were not signigicant in CP group and STD; early symptom onset greatly benefited	
	1	1	Remdes	ivir		1	1
Goldman et al. [48]	Multi-centre randomized open label study (United States, Italy, Spain, Germany, Hong Kong, Singapore, South Korea, and Taiwan)	Severe COVID-19 (n=397)	Remdesivir i.v. 200 mg once on day 1 ,100 mg once for subsequent 4 days (n=200)	Remdesivir i.v. 200mg once on day1 ,100mg once for subsequent 9 days (n=197)	Clinical status at day 14 on 7- point ordinal scale; Duration of clinical improvemen t; Clinical recovery and mortality rate; adverse events and seroius adverse events	Remdesivir 5-day Vs. 10-day: No significance in clinical improvement (64% Vs. 55%) ;no difference in IMV patients; men has worse outcomes(68%)	High risk (RoB 2.0)
Grein et al. [47]	Multi-centre randomized open label study (United states,canda,ja pan)	Severe COVID-19 (n=53)	Remdesivir i.v. 200 mg once on day 1 ,100 mg once on day 2 to day 10 (n=53)	No comparison	Cumulative incidence of clinical improvemen t till day 36; mortality; adverse events or	By Day 28: 68% clinical improvement in oxygen support patients; high mortality in age \geq 70	Fair quality (NOS)

					serious adverse events		
Beigel et al. [27]	Multi-centre randomized double-blind study (USA, Denmark, UK, Greece, Germany, Korea, Mexico, Spain, Japan, Singapore)	Hospitalized adults with lower respiratory tract evident (n=1059)	Remdesivir i.v. 200 mg once day1 followed by 100 mg day 2-10 once (n=538)	Placebo (n=521)	Clinical recovery; 8- category ordinal scale; adverse or serious adverse events	Shorter recovery duration in remdesivir treated than placebo (median 11 Vs. 15 days)(P<0.001); by day 15: improvement were higher in remdesivir group (rate ratio(RR) 1.32; 95% CI, 1.12 to 1.55 , P<0.001); Ordinal score 5 (low oxygen support) benefited the most (RR 1.47 (95% CI, 1.17 to 1.84); age 18 to <40 had highest recovery (RR 2.03 95% CI 1.31-315)	Low risk (RoB 2.0)
Wang et al. [28]	Multi-centre randomized double-blind study (China)	Severe COVID-19 adults (n=236)	Remdesivir i.v. 200 mg once day1 followed by 100 mg day2-10 once (n=158)	Placebo (n=78)	Live discharge; all-cause mortality at day-28; clinical improvemen t duration and a 2 point	No significance in clinical improvement duration (median 21 Vs. 23 days), 28-day mortality (14% Vs. 13%) and negative viral RNA proportions	Low risk (RoB 2.0)

			Dexameth	asone	decrease 6- point scale at day 7, 14 and 28; virological measures; adverse or serious adverse events	in remdesivir group from placebo	
Horby et al. [50]	Multi-centre randomized open label study (UK, USA and Italy)	Hospitalized with Covid- 19 (n=6425)	Dexamethasone i.v. or orally 6mg once daily for 10 days plus usual care (n=2104)	Usual care without dexamethasone (n=4321)	28-day mortality; composite outcome of IMV or death; discharge	IMV deaths lower in dexamethasone group than usual care (29.3% Vs. 41.4%); no significance in patients receiving oxygen only (23.3% Vs. 26.2%), without oxygen (17.8% Vs. 14.0%) and overall mortality (22.9 % Vs. 25.7%) at day 28	Low risk (RoB 2.0)
			Hydroxychol	oroquine			
Chen et al. [51]	Single-center randomised double-blind study (China)	Mild COVID-19 adults (n=62)	Hydroxychloroqui ne 200mg twice/day for 5 days plus standard treatment (n=31)	Standard treatment without hydroxychloroquin e (n=31)	Time to clinical recovery (TTCR); pulmonary recovery; adverse events	Shorter recovery time of body temperature (2.2 <i>Vs.</i> 3.2 days) and cough and significant improvement of pneumonia	High risk (RoB 2.0)

						(80.6% <i>Vs.</i> 54.8%) in hydroxychloroqui ne group than control; no severe side effects	
Tang et al. [52]	Multi-center open label controlled randomised study (China)	Hospitalized Patients with Covid-19 (n=150)	Hydroxychloroqui ne 1200 mg daily on dayd1-3 and 800 mg daily for 2- 3 weeks plus standard care (n=70)	Standard care without Hydroxychloroqui ne (n=80)	Negative conversion; adverse events or severe adverse events	HCQ+STD Vs. STD: No significant difference in probability of negative conversion (85.4% Vs. 81.3%); more adverse events in test group	Some concerns (RoB 2.0)
Geleris et al. [29]	Single-center observational Study (USA)	Hospitalized patients with Covid-19 (n=1376)	Hydroxychloroqui ne 600 mg twice on day 1 and 400 mg daily on days2- 5 ; Azithromycin 500 mg on day1 and 250 mg daily on days2-5 combination with HCQ (n=811)	Control without hydroxychloroquin e (n=565)	Intubation or death at regular time intervals	HCQ Vs. no HCQ: High intubation or death in test group (32.% Vs. 14.9%); HCQ use is not associated with high or low risk at intubation or death	Moderate risk (ROBINS -I)
			Lopinavir/r	itonavir			
Cao et al. [57]	Single-centre randomized open label study (China)	Hospitalized adults with Severe COVID-19 (n=199)	Lopinavir/ritonavir 400mg/100mg every 12h plus standard care for 14 days (n=99)	Standard care without Lopinavir/ritonavir (n=100)	Clinical improvemen t duration; Seven- category ordinal scale or discharge; virologic measures;	LPV-r Vs. STD: shorter ICU stay (median 6 Vs. 11 days); no significance in mortality (-5.8 95% CI, -17.3 to 5.7), clinical improvement (8.8	Some concerns (RoB 2.0)

					safety	95% CI,-3.3 to 20.9) and viral detectabilty (60.3% vs. 58.6%) at day 28; 4 gastrointestinal serious adverse events in the LPV-	
Li et al. [54]	Single-centre randomized study (China)	Mild/moderat e COVID-19 (n=86)	Treatment I: Lopinavir/ritonavir 200/50 mg twice daily for 7-14 days (n=34) OR Treatment II: Arbidol 200mg thrice 7-14 days (n=35)	Standard care without antiviral therapy (n=17)	RT-PCR negative coversion rate or chest CT improvemen t rate at day 7 and 14; Adverse events	r group LPV-r Vs. Arbidol Vs. STD: Clinical detoriation (23.5% Vs. 8.6% Vs. 11.8%) at day 7; virological measures similar among all groups ($p> 0.05$); 12 adverse or one serious adverse events in LPV-r group	High risk (RoB 2.0)
		Lp	v/r Vs Lpv/r +. Arbie	dol (test vs control)			
Deng et al. [55]	Single-center retrospective cohort study (South Korea)	Confirmed COVID-19 without Invasive ventilation (n=33)	Lopinavir/ritonavir 400 mg/100 mg every 12h. (n=16)	Arbidol 200 mg every 8h and Lopinavir/ritonavir orally 400 mg/100 mg twice daily. (n=17)	Clinical improvemen t outcomes (day14); negative conversion rate of SARS-CoV- 2; pneumonia monitoring by chest CT(day7)	LPV-r Vs. LPV-r+ Arbidol: Significance in negative viral load in patients not requiring mechanical ventilations (94% Vs. 53%) and improvement in chest CT (69% Vs. 29%)	High risk (ROBINS -I)

			Lopinavir/ritona	avir vs HCQ			
Kim et al. [56]	Single-center retrospective cohort study (South Korea)	Hospitalized patients with COVID-19 (n=65)	Lopinavir/ritonavir 400 mg/100 mg twice daily (n=31)	Hydroxychloroqui ne 400 mg once daily (n=34)	Time to negative conversion of viral RNA; time to clinical improvemen t; adverse events or serious adverse events	LPV-r Vs. HCQ: Shorter time to negative conversion of viral RNA (median 21 Vs. 28 days), no significant in time to clinical improvement (median 18 Vs. 21 days), negative conversion is more in patients age <65	High risk (ROBINS -I)
Rattanaumpawan et al. [59]	Multi-center retrospective observational study (Thailand)	Hospitalized adult patients with COVID- 19 (n=63)	Favipiravir 400 mg twice on day1 followed by 600 mg twice on days2-5 plus standard care (n=63)	No comparison	Clinical improvemen t; mortality; adverse events	Favipiravir: Rate of clinical improvement is less and slow in patients receiving oxygen (ambient <i>Vs.</i> receiving O2: day7 - 92.6% Vs. 47.2%; day-28 100% Vs. 83.3%), low mortality(7.9%), no severe adverse events	Fair quality (NOS)
Doi et al. [58]	Mulit-center observational study (Japan)	Confirmed COVID-19 patients (n=2158)	Favipiravir 1600 mg twice on day1 and 600 mg or 800 mg twice daily for the following days(n=2158)	No comparison	Clinical status and outcome at day7, day14 and after 1 month;	Favipiravir: Higher mortality among age group $\geq 60 (92.37\%);$ less effective for patients receiving	Poor quality (NOS)

					adverse events	oxygen	
		Favipiravi	r Vs. Lopinavir/riton	avir (both with IFN a	alpha)		
Cai et al. [66]	Single-centre non- randomized open label study (China)	Confirmed COVID-19 patients (n=80)	Favipiravir 1600 mg twice on Day1 and 600 mg twice daily on days 2–14 (n=45)	Lopinavir 400 mg /Ritonavir 100 mg twice daily (n=35).	Clinical improvemen t; viral clearance time; chest CT improvemen t; adverse events	Favirpiravir Vs. LPV-r: Shorter time of viral clearance (median 4 Vs. 11 days) ; High significant improvement rate in chest CT (91.4% Vs. 62.22%) ; more adverse events in LPV-r arm; treatment duration in favipiravir arm can be extended if required	Moderate risk (ROBINS -I)
			Nafamostat mesylat	e + Favipiravir			
Doi et al. [64]	Single-center case series (Japan)	Critically ill COVID-19 (n=11)	Favipiravir i.v. 3600 mg on day 1 and 1600 mg subsequent days plus Nafamostat mesylate continuous i.v. 0.2 mg per kg per hour (n=11)	No comparison	Live discharge; mortality	Favipiravir with Nafamostat mesylate is effective in critically ill patients; low mortality (9%)	Poor quality (NOS)

Favipiravir Vs. Arbidol										
Chen et al. [60]	Multi-centre prospective randomized controlled open label study (China)	Adult patients with COVID-19 (n=236)	Favipiravir 1600 mg twice on day1 and 600 mg twice daily for the following days(n=116)	Arbidol 200 mg three times daily plus standard care for 7 days (n=120)	Clinical recovery at Day 7; Latency to relief for pyrexia and cough; rate of noninvasive mechanical ventilation; adverse events	Favipiravir(FPV) Vs. LPV-r: No significance in clinical recovery between two groups (P=0.1396) ,improvement in latency to relief for pyrexia and cough is significant in FPV arm, effective for moderate COVID- 19 patients	Low risk (RoB 2.0)			

Acknowledgment

We thank Abhimanyu Swaroop, IIT-Madras for assistance with screening of articles during the initial phase of study.

Ethical permission

This study did not require ethical approvals as there was no direct involvement of patients.

Declaration of interests

The authors declare that they have no competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Funding

There was no funding provided for this work



Figure 1: PRISMA Flow diagram



Figure 2. Risk of bias assessment for (a) Randomised controlled trails using Cochrane risk of bias (b) Non-randomized controlled trials using Newcastle-Ottawa scale

	Control		Test								
Author, Drug	Survived	Died	Surviv	ed Die	d					Oa	ds Ratio [95% Cl]
Mild/Moderate											
Ji-Won Kim, LPV-r_vs_HCQ	33	1	30	1		н———	-				0.91 [0.05, 15.18]
Lisi deng, Arbidol+LPV-r_vs_LPV-r	17	0	16	0			-				0.94 [0.02, 50.32]
Qingxian Cai, Favipiravir_vs_LPV-r	45	0	35	0			-				0.78 [0.02, 40.30]
YuepingLi, LPV-r	17	0	34	0	F		_				1.97 [0.04, 103.61]
Wei Tang, Hydroxychloroquine	75	0	75	0			-+-				1.00 [0.02, 51.05]
Zhaowei Chen, Hydroxychloroquine	31	0	31	0	—		-÷				1.00 [0.02, 51.98]
Chang Chen, Arbidol_vs_Favipiravir	120	0	116	0			+				0.97 [0.02, 49.13]
YuepingLi, Arbidol	17	0	35	0	F			-			2.03 [0.04, 106.57]
RE Model for Mild/Moderate group (Q = 0.24, df = 7, p = 1.00; I ² = 0	.0%)					-					1.10 [0.29, 4.11]
Severe											
Joshua Geleris, Hydroxychloroquine	490	75	654	157			H B H				0.64 [0.47, 0.86]
Ruggero Capraa, Tocilizumab_vs_control(HCQ/LPV-r)	12	11	60	2					-	-	27.50 [5.39, 140.24]
Corrado Campochiaro, Tocilizumab	22	11	27	5			÷				2.70 [0.82, 8.94]
Arvind Gharbharan, Convalescent_Plasma	32	11	37	6			÷				2.12 [0.70, 6.38]
Ling Li, Convalescent_plasma	38	12	43	8			÷	-			1.70 [0.63, 4.59]
Yeming Wang, Remdesivir	68	10	136	22		1		4			0.91 [0.41, 2.03]
John H. Beigel, Remdesivir	466	55	505	33			H	н			1.81 [1.15, 2.83]
Peter Horby, Dexamethasone	3256	1065	1650	454			-				1.19 [1.05, 1.35]
Bin cao. LPV-r	75	25	80	19			, i∔∎	-			1.40 [0.71. 2.76]
RE Model for Severe group (Q = 38.05, df = 8, p = 0.000007; I^2 = 87.5%)							-	•			1.58 [0.97, 2.57]
RE Model for all studies (Q = 38.30, df = 16, p = 0.001; 1 ² = 72.2%))						•	•			1.48 [0.98, 2.23]
					1	1	i	1	1		
				0	0.02	0.14	1	7.39	54.6	403.43	
						0	dds R	atio			

Figure 3. Forest plot comparing mortality of patients between control and test group and subgrouped based on severity level of disease. CI, confidence interval; df, degrees of freedom; I^2 , heterogeneity. Line of no effect is at 1. Each horizontal bar represents upper and lower 95% CI. Squares on the right and left side of the line favor the test and control group respectively. Diamond shows an overall summary of all studies

Events Total Proportion Study 95%-CI Jason D. Goldman, Remdesivir 16 192 0.08 [0.05; 0.13] 188 Jason D. Goldman, Remdesivir 21 0.11 [0.07; 0.17] Jonathan Grein, Remdesivir 7 53 0.13 [0.05; 0.25] 2 28 Krzysztof Tomasiewicz, Tocilizumab 0.07 [0.01; 0.24] 7 Savino Sciascia, Tocilzumab 63 0.11 [0.05; 0.22] 20 100 Paola Toniati, Tocilizumab 0.20 [0.13; 0.29] 82 Adrian, Tocilizumab 22 0.27 [0.18; 0.38] 223 1918 Yohei Doi, Favipiravir 0.12 [0.10; 0.13] Kent Doi, Nafamostat mesylate+Favipiravir 1 11 0.09 [0.00; 0.41] Pinyo Rattanaumpawan, Favipiravir 3 63 0.05 [0.01; 0.13] Fixed effect model 2698 0.12 [0.11; 0.13] Random effects model 0.12 [0.09; 0.16] Heterogeneity: $I^2 = 72\%$, $\tau^2 = 0.1662$, p < 0.010.1 0.2 0.3 0.4

Figure 4: Forest plot of the proportion of death events occurred in different single armed drug trials. Squares on the right side show a higher proportion of death events in the population



Figure 5. Meta-regression showing the correlation of patient population on TCZ with treatment characteristics and comorbidities. (a) correlation of patients under non-invasive therapy with treatment characteristics (b) correlation of patients under non-invasive therapy with comorbidities (c) correlation of patients under invasive therapy with treatment characteristics (d) correlation of patients under invasive therapy with comorbidities.



Figure 6. Histogram showing clinical outcomes of all the treatments comparing control and test groups. The top and bottom plot represents the percentage of patients and time period for each clinical outcome category respectively. The empty bars for few categories represent missing data

References

1. Azkur AK, Akdis M, Azkur D, et al. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy 2020; 75:1564–1581

2. Espejo W, Celis JE, Chiang G, et al. Environment and COVID-19: Pollutants, impacts, dissemination, management and recommendations for facing future epidemic threats. Sci. Total Environ. 2020; 747:141314

3. Mansueto G, Niola M, Napoli C. Can COVID 2019 induce a specific cardiovascular damage or it exacerbates pre-existing cardiovascular diseases? Pathol. - Res. Pract. 2020; 216:153086

4. Zhu L, She Z-G, Cheng X, et al. Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes. Cell Metab. 2020; 31:1068-1077.e3

5. Takahashi T, Ellingson MK, Wong P, et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature 2020;

Guan W, Ni Z, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N.
 Engl. J. Med. 2020; 382:1708–1720

7. Guo Y-R, Cao Q-D, Hong Z-S, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Mil. Med. Res. 2020;
7:11

 Lee N, Hui D, Wu A, et al. A Major Outbreak of Severe Acute Respiratory Syndrome in Hong Kong. N. Engl. J. Med. 2003; 348:1986–1994

9. Peiris J, Lai S, Poon L, et al. Coronavirus as a possible cause of severe acute respiratory

syndrome. Lancet 2003; 361:1319–1325

10. de Wit E, van Doremalen N, Falzarano D, et al. SARS and MERS: recent insights into emerging coronaviruses. Nat. Rev. Microbiol. 2016; 14:523–534

11. Alagaili AN, Briese T, Mishra N, et al. Middle East Respiratory Syndrome Coronavirus Infection in Dromedary Camels in Saudi Arabia. MBio 2014; 5:

12. Memish ZA, Mishra N, Olival KJ, et al. Middle East Respiratory Syndrome Coronavirus in Bats, Saudi Arabia. Emerg. Infect. Dis. 2013; 19:

13. Zaki AM, van Boheemen S, Bestebroer TM, et al. Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia. N. Engl. J. Med. 2012; 367:1814–1820

14. Funnell SGP, Dowling WE, Muñoz-Fontela C, et al. Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients. Nat. Commun. 2020; 11:4253

15. Brown BL, McCullough J. Treatment for emerging viruses: Convalescent plasma and COVID-19. Transfus. Apher. Sci. 2020; 59:102790

16. Meleveedu KS, Miskovsky J, Meharg J, et al. Tocilizumab for severe COVID-19 related illness – A community academic medical center experience. Cytokine X 2020; 2:100035

17. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339:b2700–b2700

18. Wickham H. ggplot2. 2016;

19. Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in

randomised trials. BMJ 2019; 14898

20. Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in nonrandomised studies of interventions. BMJ 2016; i4919

21. McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. Res. Synth. Methods 2020; jrsm.1411

22. Lo CK-L, Mertz D, Loeb M. Newcastle-Ottawa Scale: comparing reviewers' to authors' assessments. BMC Med. Res. Methodol. 2014; 14:45

23. Bae J-M. A suggestion for quality assessment in systematic reviews of observational studies in nutritional epidemiology. Epidemiol. Health 2016; 38:e2016014

24. Viechtbauer W. Conducting Meta-Analyses in *R* with the **metafor** Package. J. Stat. Softw. 2010; 36:

25. Nyaga VN, Arbyn M, Aerts M. Metaprop: a Stata command to perform meta-analysis of binomial data. Arch. Public Heal. 2014; 72:39

26. Capra R, De Rossi N, Mattioli F, et al. Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia. Eur. J. Intern. Med. 2020; 76:31–35

27. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 — Preliminary Report. N. Engl. J. Med. 2020; NEJMoa2007764

28. Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020; 395:1569–1578

29. Geleris J, Sun Y, Platt J, et al. Observational Study of Hydroxychloroquine in Hospitalized

Patients with Covid-19. N. Engl. J. Med. 2020; 382:2411-2418

30. Sanchez-Montalva A, Selares-Nadal J, Espinosa-Pereiro J, et al. Early outcomes of tocilizumab in adults hospitalized with severe COVID19. An initial report from the Vall dHebron COVID19 prospective cohort study. medRxiv 2020;

31. Toniati P, Piva S, Cattalini M, et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy. Autoimmun. Rev. 2020; 19:102568

32. Mahase E. Covid-19: death rate is 0.66% and increases with age, study estimates. BMJ 2020; m1327

33. Scott LJ. Tocilizumab: A Review in Rheumatoid Arthritis. Drugs 2017; 77:1865–1879

34. Coperchini F, Chiovato L, Croce L, et al. The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system. Cytokine Growth Factor Rev. 2020; 53:25–32

35. Campochiaro C, Della-Torre E, Cavalli G, et al. Efficacy and safety of tocilizumab in severe
COVID-19 patients: a single-centre retrospective cohort study. Eur. J. Intern. Med. 2020; 76:43–
49

36. De Rossi N, Scarpazza C, Filippini C, et al. Early use of low dose tocilizumab in patients with COVID-19: A retrospective cohort study with a complete follow-up. EClinicalMedicine 2020; 25:100459

37. Guaraldi G, Meschiari M, Cozzi-Lepri A, et al. Tocilizumab in patients with severe COVID19: a retrospective cohort study. Lancet Rheumatol. 2020; 2:e474–e484

 Klopfenstein T, Zayet S, Lohse A, et al. Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients. Médecine Mal. Infect. 2020; 50:397–400
 Tomasiewicz K, Piekarska A, Stempkowska-Rejek J, et al. Tocilizumab for patients with severe COVID-19: a retrospective, multi-center study. Expert Rev. Anti. Infect. Ther. 2020; 1–8
 Sciascia S, Aprà F, Baffa A, et al. Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19. Clin. Exp. Rheumatol. 2020; 38:529–532

41. Cortegiani A, Ippolito M, Greco M, et al. Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review. Pulmonology 2020;

42. Rilinger J, Kern W V., Duerschmied D, et al. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial. Trials 2020; 21:470

43. Gharbharan A, Jordans CC, GeurtsvanKessel C, et al. Convalescent Plasma for COVID-19. A randomized clinical trial. MEDRxiv 2020;

44. Li L, Zhang W, Hu Y, et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19. JAMA 2020; 324:460

45. Agarwal A, Mukherjee A, Kumar G, et al. Convalescent plasma in the management of moderate COVID-19 in India: An open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial). MedRxiv 2020;

46. Bonovas S, Piovani D. Compassionate Use of Remdesivir in Covid-19. N. Engl. J. Med.

2020; 382:e101

47. Grein J, Ohmagari N, Shin D, et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N. Engl. J. Med. 2020; 382:2327–2336

48. Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N. Engl. J. Med. 2020; NEJMoa2015301

49. Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19. JAMA 2020; 324:1048

50. Horby P, Mafham M, Linsell L, et al. Dexamethasone in Hospitalized Patients with Covid-19
— Preliminary Report. N. Engl. J. Med. 2020; NEJMoa2021436

51. Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. MedRxiv 2020;

52. Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ 2020; 369:m1849

53. Rother N, Yanginlar C, Lindeboom RG, et al. Hydroxychloroquine inhibits trained immunity-implications for COVID-19. medRxiv 2020;

54. Li Y, Xie Z, Lin W, et al. Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial. Med 2020;

55. Deng L, Li C, Zeng Q, et al. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study. J. Infect. 2020; 81:e1–e5 56. Kim J-W, Kim EJ, Kwon HH, et al. Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019. Korean J. Intern. Med. 2020;

57. Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. N. Engl. J. Med. 2020; 382:1787–1799

58. Doi Y, Kondo M, Matsuyama A. Preliminary Report of the Favipiravir Observational Study in Japan. 2020;

59. Rattanaumpawan P, Jirajariyavej S, Lerdlamyong K, et al. Real-world Experience with Favipiravir for Treatment of COVID-19 in Thailand: Results from a Multi-center Observational Study. medRxiv 2020;

60. Chen C, Huang J, Cheng Z, et al. Favipiravir versus arbidol for COVID-19: a randomized clinical trial. MedRxiv 2020;

61. Fear G, Komarnytsky S, Raskin I. Protease inhibitors and their peptidomimetic derivatives as potential drugs. Pharmacol. Ther. 2007; 113:354–368

62. Yamamoto M, Kiso M, Sakai-Tagawa Y, et al. The anticoagulant nafamostat potently inhibits SARS-CoV-2 infection in vitro: an existing drug with multiple possible therapeutic effects. bioRxiv 2020;

63. Hoffmann M, Schroeder S, Kleine-Weber H, et al. Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19. Antimicrob. Agents Chemother. 2020;

64. Doi K, Ikeda M, Hayase N, et al. Nafamostat mesylate treatment in combination with

favipiravir for patients critically ill with Covid-19: a case series. Crit. Care 2020; 24:392

65. Kewan T, Covut F, Al–Jaghbeer MJ, Rose L, Gopalakrishna KV, Akbik B. Tocilizumab for treatment of patients with severe COVID–19: A retrospective cohort study. EClinicalMedicine. 2020; 24:100418

66. Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, Liao X, Gu Y, Cai Q, Yang Y, Shen C.Experimental treatment with favipiravir for COVID-19: an open-label control study.Engineering. 2020